Stock Analysis

Careplus Group Berhad First Quarter 2025 Earnings: RM0.01 loss per share (vs RM0.14 loss in 1Q 2024)

KLSE:CAREPLS
Source: Shutterstock

Careplus Group Berhad (KLSE:CAREPLS) First Quarter 2025 Results

Key Financial Results

  • Revenue: RM27.0m (up 122% from 1Q 2024).
  • Net loss: RM7.40m (loss narrowed by 91% from 1Q 2024).
  • RM0.01 loss per share (improved from RM0.14 loss in 1Q 2024).
earnings-and-revenue-history
KLSE:CAREPLS Earnings and Revenue History November 21st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Careplus Group Berhad's share price is broadly unchanged from a week ago.

Risk Analysis

You still need to take note of risks, for example - Careplus Group Berhad has 4 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KLSE:CAREPLS

Careplus Group Berhad

An investment holding company, engages in the manufacture and processing of gloves in South America, North America, Malaysia, rest of Asia Pacific, and internationally.

Adequate balance sheet and slightly overvalued.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor